MEK targeting in N-RAS mutated metastatic melanoma

Disease progression and patient survival are significantly influenced by BRAF protein expression in primary melanoma

(2013) G. Safaee Ardekani et al.   BRITISH JOURNAL OF DERMATOLOGY

Low BRAF and NRAS expression levels are associated with clinical benefit from DTIC therapy and prognosis in metastatic melanoma

(2013) Einar Birkeland et al.   CLINICAL & EXPERIMENTAL METASTASIS

Advances in therapy for melanoma brain metastases

(2013) Jaclyn C. Flanigan et al.   CLINICS IN DERMATOLOGY

Molecularly targeted therapies for melanoma

(2013) Lucinda S. Liu et al.   INTERNATIONAL JOURNAL OF DERMATOLOGY

Clonal BRAF Mutations in Melanocytic Nevi and Initiating Role of BRAF in Melanocytic Neoplasia

(2013) Iwei Yeh et al.   JNCI-Journal of the National Cancer Institute

MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study

(2013) Paolo A Ascierto et al.   LANCET ONCOLOGY

A Landscape of Driver Mutations in Melanoma

(2012) Eran Hodis et al.   CELL

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial

(2012) Gerald S Falchook et al.   LANCET

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

(2012) Axel Hauschild et al.   LANCET

Combinations of BRAF, MEK, and PI3K/mTOR Inhibitors Overcome Acquired Resistance to the BRAF Inhibitor GSK2118436 Dabrafenib, Mediated by NRAS or MEK Mutations

(2012) J. G. Greger et al.   MOLECULAR CANCER THERAPEUTICS

Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma

(2012) Michael Krauthammer et al.   NATURE GENETICS

Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma

(2012) Lawrence N Kwong et al.   NATURE MEDICINE

Vemurafenib: the first drug approved for BRAF-mutant cancer

(2012) Gideon Bollag et al.   NATURE REVIEWS DRUG DISCOVERY

Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

(2012) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma

(2012) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity

(2012) T. Maurer et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

NRAS mutation status is an independent prognostic factor in metastatic melanoma

(2011) John A. Jakob et al.   CANCER

Phase II, Open-Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced Melanoma

(2011) J. M. Kirkwood et al.   CLINICAL CANCER RESEARCH

Inhibition of Ras for cancer treatment: the search continues

(2011) Antonio T Baines et al.   Future Medicinal Chemistry

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

(2010) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Hyperactivation of MEK–ERK1/2 signaling and resistance to apoptosis induced by the oncogenic B-RAF inhibitor, PLX4720, in mutant N-RAS melanoma cells

(2010) F M Kaplan et al.   ONCOGENE

PLX4032, a selective BRAFV600E kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAFWT melanoma cells

(2010) Ruth Halaban et al.   Pigment Cell & Melanoma Research

Ras oncogenes: split personalities

(2008) Antoine E. Karnoub et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY